J 2025

Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumab

FIALA, Ondrej; Katarina REJLEKOVA; Tomas BUCHLER; Hana STUDENTOVA; Alexandr POPRACH et al.

Basic information

Original name

Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumab

Authors

FIALA, Ondrej; Katarina REJLEKOVA; Tomas BUCHLER; Hana STUDENTOVA; Alexandr POPRACH; Michal VOCKA; Petr HOSEK; Jindrich KOPECKY; Martin MATEJU; Anezka ZEMANKOVA; Martina SPISAROVA; Michaela TKADLECOVA; Peter PRIESTER; Jan KOURIL; Radka LOHYNSKA; Lucie GRMELOVA; Alexander SAVKA; Katarina STEFANIKOVA; Jana OBERTOVA; Dominika SIKOVA; Petr STRANSKY; Bohuslav MELICHAR and Patrik PALACKA

Edition

SCIENTIFIC REPORTS, England, NATURE PORTFOLIO, 2025, 2045-2322

Other information

Language

English

Type of outcome

Article in a journal

Country of publisher

Germany

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Marked to be transferred to RIV

No

Organization

Lékařská fakulta – Repository – Repository

DOI

https://doi.org/10.1038/s41598-025-32593-8

UT WoS

001667610600001

EID Scopus

2-s2.0-105028305510

Keywords in English

Renal cell carcinoma; Eosinophils; Neutrophil-to-eosinophil ratio; Immunotherapy; Nivolumab

Links

LX22NPO5102, research and development project.
Changed: 27/2/2026 00:51, RNDr. Daniel Jakubík

Abstract

In the original language

lt; 65 (p = 0.025). The results of the present study suggest that eosinophil-based blood parameters including AEC and NER and their early dynamics during the course of treatment with nivolumab are promising and readily available prognostic biomarkers in patients with mRCC.
Displayed: 22/6/2026 08:04